Vinorelbine should be given only under the supervision of a doctor with experience in the use of chemotherapy medications.
Vinorelbine can cause a severe decrease in the number of blood cells in your bone marrow. This may cause certain symptoms and may increase the risk that you will develop a serious infection. Your doctor will order laboratory tests before and during your treatment to check the number of white blood cells in your blood. Your doctor may decrease your dose, or delay,, interrupt, or stop your treatment if the number of white blood cells is too low. If you experience any of the following symptoms, call your doctor immediately: fever, sore throat, ongoing cough and congestion, or other signs of infection.
Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests to check your body's response to vinorelbine.
Vinorelbine is used alone and in combination with other medications to treat non-small cell lung cancer (NSCLC) that has spread to nearby tissues or to other parts of the body. Vinorelbine is in a class of medications called vinca alkaloids. It works by slowing or stopping the growth of cancer cells in your body.
Vinorelbine comes as a solution (liquid) to be injected intravenously (into a vein) by a doctor or nurse in a medical facility. It is usually given once a week. The length of treatment depends on how well your body responds to treatment with vinorelbine.
You should know that vinorelbine should be administered only into a vein. However, it may leak into surrounding tissue causing severe irritation or damage. Your doctor or nurse will monitor the area near where the medication was injected. If you experience any of the following symptoms, tell your doctor immediately: pain, itching, redness, swelling, blisters, or sores near the place where the medication was injected.
Vinorelbine is also sometimes used to treat breast cancer, cancer of the esophagus (tube that connects the mouth and stomach), and soft tissue sarcomas (cancer that forms in muscles). Talk to your doctor about the risks of using this medication for your condition.
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
Before receiving vinorelbine,
Your doctor may tell you to be sure to drink enough of water, and eat high fiber foods such as lettuce, spinach, broccoli, squashes, beans, nuts, seeds, fruit, whole wheat bread, whole wheat pasta, or brown rice. Be sure to follow the instructions carefully.
Vinorelbine may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
Some side effects can be serious. If you experience any of these symptoms or those listed in the IMPORTANT WARNING section, call your doctor immediately or get emergency medical treatment:
Talk to your doctor about the risks of receiving vinorelbine injection.
Vinorelbine may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.
If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online ( Web Site ) or by phone (1-800-332-1088).
In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at Web Site. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.
Symptoms of overdose may include:
It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.
AHFS® Consumer Medication Information. © Copyright, The American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland. All Rights Reserved. Duplication for commercial use must be authorized by ASHP.
Selected Revisions: July 15, 2019.